DE2503442A1 - Antivirale substanzen, verfahren zu ihrer herstellung und diese substanzen enthaltende arzneimittel - Google Patents
Antivirale substanzen, verfahren zu ihrer herstellung und diese substanzen enthaltende arzneimittelInfo
- Publication number
- DE2503442A1 DE2503442A1 DE19752503442 DE2503442A DE2503442A1 DE 2503442 A1 DE2503442 A1 DE 2503442A1 DE 19752503442 DE19752503442 DE 19752503442 DE 2503442 A DE2503442 A DE 2503442A DE 2503442 A1 DE2503442 A1 DE 2503442A1
- Authority
- DE
- Germany
- Prior art keywords
- double
- stranded
- antiviral
- antiviral substances
- natural origin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000126 substance Substances 0.000 title claims description 35
- 230000000840 anti-viral effect Effects 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title description 4
- 229940126601 medicinal product Drugs 0.000 title description 3
- 229920002477 rna polymer Polymers 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229920000447 polyanionic polymer Polymers 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 10
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 241000228143 Penicillium Species 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 241000892910 Aspergillus foetidus Species 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000012876 carrier material Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 2
- 241000228150 Penicillium chrysogenum Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008151 electrolyte solution Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000710188 Encephalomyocarditis virus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 241000228245 Aspergillus niger Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000228145 Penicillium brevicompactum Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 239000002799 interferon inducing agent Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000702662 Cypovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB420774A GB1458586A (en) | 1974-01-29 | 1974-01-29 | Antiviral complexes of double stranded rna and its derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2503442A1 true DE2503442A1 (de) | 1975-07-31 |
Family
ID=9772754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752503442 Withdrawn DE2503442A1 (de) | 1974-01-29 | 1975-01-28 | Antivirale substanzen, verfahren zu ihrer herstellung und diese substanzen enthaltende arzneimittel |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US3978043A (en, 2012) |
| JP (1) | JPS50116620A (en, 2012) |
| BE (1) | BE824947A (en, 2012) |
| CA (1) | CA1042877A (en, 2012) |
| CH (1) | CH613118A5 (en, 2012) |
| DE (1) | DE2503442A1 (en, 2012) |
| DK (1) | DK141194B (en, 2012) |
| FR (1) | FR2258862B1 (en, 2012) |
| GB (1) | GB1458586A (en, 2012) |
| IL (1) | IL46524A (en, 2012) |
| NL (1) | NL7500955A (en, 2012) |
| SE (1) | SE400976B (en, 2012) |
| ZA (1) | ZA75540B (en, 2012) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0116693A1 (en) * | 1982-11-27 | 1984-08-29 | Microbial Chemistry Research Foundation | An immunopotentiator having spermidine or its pharmacologically acceptable salt as active ingredient |
| US5091374A (en) * | 1987-07-17 | 1992-02-25 | Hem Research Inc. | Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3484521A (en) * | 1966-06-23 | 1969-12-16 | Int Chem & Nuclear Corp | Enhancement of memory processes in mammals with basic addition salts of ribonucleic acid |
| BR6801650D0 (pt) * | 1968-08-20 | 1973-03-07 | R Maes | Processo para preparacao de complexos geradores de interferon |
| BE790953A (fr) * | 1971-11-05 | 1973-05-03 | Beecham Group Ltd | Matiere biologiquement active |
-
1974
- 1974-01-29 GB GB420774A patent/GB1458586A/en not_active Expired
-
1975
- 1975-01-27 US US05/544,211 patent/US3978043A/en not_active Expired - Lifetime
- 1975-01-27 SE SE7500854A patent/SE400976B/xx unknown
- 1975-01-27 ZA ZA00750540A patent/ZA75540B/xx unknown
- 1975-01-28 CA CA218,867A patent/CA1042877A/en not_active Expired
- 1975-01-28 DE DE19752503442 patent/DE2503442A1/de not_active Withdrawn
- 1975-01-28 NL NL7500955A patent/NL7500955A/xx not_active Application Discontinuation
- 1975-01-29 IL IL46524A patent/IL46524A/xx unknown
- 1975-01-29 JP JP50012299A patent/JPS50116620A/ja active Pending
- 1975-01-29 BE BE152853A patent/BE824947A/xx unknown
- 1975-01-29 FR FR7502721A patent/FR2258862B1/fr not_active Expired
- 1975-01-29 DK DK30375AA patent/DK141194B/da unknown
- 1975-01-29 CH CH102875A patent/CH613118A5/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0116693A1 (en) * | 1982-11-27 | 1984-08-29 | Microbial Chemistry Research Foundation | An immunopotentiator having spermidine or its pharmacologically acceptable salt as active ingredient |
| US5091374A (en) * | 1987-07-17 | 1992-02-25 | Hem Research Inc. | Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function |
Also Published As
| Publication number | Publication date |
|---|---|
| DK141194B (da) | 1980-02-04 |
| AU7770075A (en) | 1976-07-29 |
| CA1042877A (en) | 1978-11-21 |
| IL46524A (en) | 1978-10-31 |
| BE824947A (fr) | 1975-07-29 |
| SE7500854L (en, 2012) | 1975-07-30 |
| DK30375A (en, 2012) | 1975-09-22 |
| GB1458586A (en) | 1976-12-15 |
| IL46524A0 (en) | 1975-05-22 |
| SE400976B (sv) | 1978-04-17 |
| CH613118A5 (en, 2012) | 1979-09-14 |
| NL7500955A (nl) | 1975-07-31 |
| FR2258862B1 (en, 2012) | 1980-02-08 |
| FR2258862A1 (en, 2012) | 1975-08-22 |
| DK141194C (en, 2012) | 1980-07-21 |
| JPS50116620A (en, 2012) | 1975-09-12 |
| US3978043A (en) | 1976-08-31 |
| ZA75540B (en) | 1976-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004037865A1 (de) | Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel | |
| DE3045078A1 (de) | Nucleasebestaendiger hydrophiler komplex aus polyriboinosinsaeure, verfahren zu seiner herstellung und verwendung desselben | |
| DE2253977C2 (de) | Antiviraler Komplex, Verfahren zu seiner Herstellung und diesen Komplex enthaltende Arzneimittel | |
| DE3118588C2 (de) | Verfahren zur Herstellung eines injizierbaren hochreinen Chondroitinpolysulfates, hiernach erhältliches Produkt und pharmazeutische Zusammensetzung | |
| CH616432A5 (en, 2012) | ||
| DE2435746C2 (en, 2012) | ||
| DE69803362T2 (de) | O-sulfatierte, bakterielle polysaccharide | |
| DE3416609A1 (de) | 2-amino-3-ethoxycarbonylamino-6-(p-fluor-benzylamino)- pyridin-gluconat und pharmazeutische zubereitungen, die diese substanz enthalten | |
| DE69733492T2 (de) | Verfahren und zusammensetzung zur behandlung von mykosen in tieren | |
| DE2234474A1 (de) | Verfahren zur herstellung fein verteilter mikropartikel von tyrosin mit einem gehalt eines darin dispergierten allergens und diese produkte enthaltende arzneipraeparate | |
| DE2503442A1 (de) | Antivirale substanzen, verfahren zu ihrer herstellung und diese substanzen enthaltende arzneimittel | |
| DE2753312A1 (de) | Heteropolyanionverbindungen, ihre herstellung und sie enthaltende arzneimittel | |
| DE3328372A1 (de) | Imidazolidinyl-harnstoff und parabene enthaltende zusammensetzung | |
| DE2606106A1 (de) | Hydroxyamine, verfahren zu deren herstellung und verwendung derselben | |
| DE1768972A1 (de) | Substituierte Vinylphosphate als Wurmmittel und Verfahren zu ihrer Herstellung | |
| DE2022656B2 (de) | 2-(Nicotinoylaminoäthansulfonylamino)pyridin | |
| DE2036935C3 (de) | Diisonicotinsäurehydrazid-methansulfonat des d(+)2^>-(Äthylendiimino)-di-lbutanols, Verfahren zur Herstellung desselben und diese Verbindung enthaltende Arzneimittel | |
| DE2105095A1 (de) | Dibasisches Aluminiumhistidinat | |
| US4018916A (en) | Antiviral ionic complexes of double-standard RNA | |
| DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
| DE2064296C2 (de) | Verfahren zur Herstellung eines injizierbaren Mittels gegen Viren der Mäuseleukämien | |
| DE2359621C2 (de) | Antiviral wirksame Alkalimetall- oder Ammoniumsalze der Polyacrylsäure | |
| DE2803681C2 (en, 2012) | ||
| DE3515178A1 (de) | Verfahren zur herstellung von neuen anthracyclinkonjugaten anionischer polymerer | |
| DE2104851B2 (de) | Verwendung von Acrylsäure-Polymerisaten bei der Behandlung von Hypersekretion des Magens oder Duodenums |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8125 | Change of the main classification | ||
| 8126 | Change of the secondary classification | ||
| 8130 | Withdrawal |